The primary endpoint rates were 37 and 41 % in the flecainide ( 143 19 mg/day ) and control groups , respectively ( log-rank P = 0.76 ) , and those of the secondary endpoint were 10 and 14 % , respectively ( log-rank P = 0.45 ) .